{"id":927886,"date":"2026-01-15T16:04:43","date_gmt":"2026-01-15T21:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/"},"modified":"2026-01-15T16:04:43","modified_gmt":"2026-01-15T21:04:43","slug":"oncolytics-biotech-announces-results-of-special-meeting-of-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/","title":{"rendered":"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders"},"content":{"rendered":"<h2>\nAll resolutions passed, enabling the Company to streamline regulatory and operational processes<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Jan.  15, 2026  (GLOBE NEWSWIRE) &#8212; Oncolytics Biotech<sup>\u00ae<\/sup> Inc. (Nasdaq: ONCY) (\u201c<strong>Oncolytics<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the \u201c<strong>Special Meeting<\/strong>\u201d) held on Thursday, January 15, 2026.<\/p>\n<p align=\"justify\">Each item of business described in the management information circular\/prospectus of the Company dated December 9, 2025, was approved by the shareholders. The voting results for each item of business are set out below.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:48%;width:48%;min-width:48%;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Resolution<\/strong>\n          <\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>For<\/strong>\n          <\/td>\n<td colspan=\"1\" style=\"max-width:13%;width:13%;min-width:13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>%<\/strong>\n          <\/td>\n<td style=\"max-width:13%;width:13%;min-width:13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Against<\/strong>\n          <\/td>\n<td colspan=\"1\" style=\"max-width:13%;width:13%;min-width:13%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>%<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Continuance Resolution<\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">14,994,075<\/td>\n<td style=\"padding-right: 0;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">85.21%<\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2,602,405<\/td>\n<td style=\"padding-right: 0;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">14.79%<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Domestication Resolution<\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">15,304,574<\/td>\n<td style=\"padding-right: 0;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">86.98%<\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2,291,905<\/td>\n<td style=\"padding-right: 0;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">13.02%<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2026 Incentive Award Plan Resolution<\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">13,508,657<\/td>\n<td style=\"padding-right: 0;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">76.77%<\/td>\n<td style=\"text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">4,087,822<\/td>\n<td style=\"padding-right: 0;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">23.23%<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">The approval of the first resolution authorized the Company to continue from the Province of Alberta in Canada to the Province of British Columbia in Canada (the \u201c<strong>Continuance<\/strong>\u201d). The approval of the second resolution authorized the Company to continue from the Province of British Columbia to the State of Nevada in the United States of America (the \u201c<strong>Domestication<\/strong>\u201d). The approval of the third resolution authorized the Company to implement the Oncolytics Biotech Inc. 2026 Incentive Award Plan (the \u201c<strong>2026 Incentive Award Plan<\/strong>\u201d), subject to and conditional upon the completion of the Continuance and Domestication.<\/p>\n<p align=\"justify\">The Company expects to consummate the Continuance and Domestication, and for the 2026 Incentive Award Plan to become effective at the end of the first quarter of 2026.<\/p>\n<p align=\"justify\">For more details on the matters covered at the Special Meeting, please refer to the Company\u2019s public filings available on SEDAR+ at\u00a0https:\/\/www.sedarplus.ca\/home\/ and on EDGAR at https:\/\/www.sec.gov\/.<\/p>\n<p align=\"justify\">\n        <strong>About Oncolytics Biotech Inc.<\/strong><br \/>\n        <br \/>Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically \u201ccold\u201d tumors \u201chot\u201d through the activation of innate and adaptive immune responses.<\/p>\n<p align=\"justify\">The Company is advancing pelareorep in combination with chemotherapy and\/or checkpoint inhibitors in metastatic pancreatic and breast cancers, of which both development programs have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rEaaeZxAxcXddZ2G1BHAwOGI0xhtP1T9YNJoC9HGuPzU2DZWbmVCFc5gv6BvQY0qGV9avY2muq1i3sNPGidzKGgN3LD92fY9X65DPcuid5aGDvUrSO6xe1VCaVBqU0SE\" rel=\"nofollow\" target=\"_blank\">www.oncolyticsbiotech.com<\/a> or follow the Company on social media on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kC8FRj_c9VFEFImHQ7g10QpRa_CN80I4p-IoYAI7EOUuOKvzlfINBfWrUDV7xvaOtIp2I5W1Y3B5ZnCqNIr6zp-l9CszlX0rg1oGSV9QT4AxfPO7IAHKg4tgd0Zx5sFm\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and on X @<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zPH3VUjN5y7au5ndO4m1nyE1g4yaWF5hK-TDI0cAeCaSBQ3aOXvOTuDj7H00-cvSUfiU7si3HEkjEbzwwPUqsw==\" rel=\"nofollow\" target=\"_blank\">oncolytics<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as \u201cforward-looking statements\u201d). Forward-looking statements contained in this press release include statements regarding the expected consummation of the Continuance and the Domestication and effectiveness of the 2026 Incentive Award Plan, and timing thereof; and the anticipated benefits of the Continuance, Domestication, and 2026 Incentive Award Plan. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics\u2019 public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Company Contact <\/strong><br \/>\n        <br \/>Jon Patton<br \/>Director of IR &amp; Communication<br \/>jpatton@oncolytics.ca<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations for Oncolytics<\/strong><br \/>\n        <br \/>Mike Moyer<br \/>LifeSci Advisors<br \/>+1-617-308-4306<br \/>mmoyer@lifesciadvisors.com<\/p>\n<p align=\"justify\">\n        <strong>Media Contact for Oncolytics<\/strong><br \/>\n        <br \/>Owen Blaschak<br \/>LifeSci Communications<br \/>oblaschak@lifescicomms.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGMxMjlkYmYtNDcyZS00MDViLTk4YjYtNGI4Nzk0MjA2Y2RkLTUwMDE1NzAwMC0yMDI2LTAxLTE1LWVu\/tiny\/Oncolytics-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>All resolutions passed, enabling the Company to streamline regulatory and operational processes SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) &#8212; Oncolytics Biotech\u00ae Inc. (Nasdaq: ONCY) (\u201cOncolytics\u201d or the \u201cCompany\u201d), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) held on Thursday, January 15, 2026. Each item of business described in the management information circular\/prospectus of the Company dated December 9, 2025, was approved by the shareholders. The voting results for each item of business are set out below. Resolution For % Against % Continuance Resolution 14,994,075 85.21% 2,602,405 14.79% Domestication Resolution 15,304,574 86.98% 2,291,905 13.02% 2026 Incentive Award Plan Resolution 13,508,657 76.77% 4,087,822 23.23% \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-927886","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"All resolutions passed, enabling the Company to streamline regulatory and operational processes SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) &#8212; Oncolytics Biotech\u00ae Inc. (Nasdaq: ONCY) (\u201cOncolytics\u201d or the \u201cCompany\u201d), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) held on Thursday, January 15, 2026. Each item of business described in the management information circular\/prospectus of the Company dated December 9, 2025, was approved by the shareholders. The voting results for each item of business are set out below. Resolution For % Against % Continuance Resolution 14,994,075 85.21% 2,602,405 14.79% Domestication Resolution 15,304,574 86.98% 2,291,905 13.02% 2026 Incentive Award Plan Resolution 13,508,657 76.77% 4,087,822 23.23% \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; Continue reading &quot;Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T21:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders\",\"datePublished\":\"2026-01-15T21:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/\"},\"wordCount\":640,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/\",\"name\":\"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==\",\"datePublished\":\"2026-01-15T21:04:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders - Market Newsdesk","og_description":"All resolutions passed, enabling the Company to streamline regulatory and operational processes SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) &#8212; Oncolytics Biotech\u00ae Inc. (Nasdaq: ONCY) (\u201cOncolytics\u201d or the \u201cCompany\u201d), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the \u201cSpecial Meeting\u201d) held on Thursday, January 15, 2026. Each item of business described in the management information circular\/prospectus of the Company dated December 9, 2025, was approved by the shareholders. The voting results for each item of business are set out below. Resolution For % Against % Continuance Resolution 14,994,075 85.21% 2,602,405 14.79% Domestication Resolution 15,304,574 86.98% 2,291,905 13.02% 2026 Incentive Award Plan Resolution 13,508,657 76.77% 4,087,822 23.23% \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 &hellip; Continue reading \"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-15T21:04:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders","datePublished":"2026-01-15T21:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/"},"wordCount":640,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/","name":"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==","datePublished":"2026-01-15T21:04:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNjY3OSM3MzY0MjI5IzUwMDE1NzAwMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncolytics Biotech\u00ae Announces Results of Special Meeting of Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=927886"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=927886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=927886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=927886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}